Derek Wallace
About
Derek Wallace is a scholar working on Public Health, Environmental and Occupational Health, Infectious Diseases and Sociology and Political Science.
According to data from OpenAlex, Derek Wallace has authored 32 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Public Health, Environmental and Occupational Health, 20 papers in Infectious Diseases and 3 papers in Sociology and Political Science. Recurrent topics in Derek Wallace's work include Mosquito-borne diseases and control (23 papers), Viral Infections and Outbreaks Research (16 papers) and Viral Infections and Vectors (15 papers). Derek Wallace is often cited by papers focused on Mosquito-borne diseases and control (23 papers), Viral Infections and Outbreaks Research (16 papers) and Viral Infections and Vectors (15 papers). Derek Wallace collaborates with scholars based in United States, Switzerland and Panama. Derek Wallace's co-authors include Chukiat Sirivichayakul, T. Anh Wartel, Dan T. Stinchcomb, Alain Bouckenooghe, Jean Lang, Mélanie Saville, Simonetta Viviani, Nadia Tornieporth, Arunee Sabchareon and Saravudh Suvannadabba and has published in prestigious journals such as The Lancet, The Journal of Infectious Diseases and PLoS Medicine.
In The Last Decade
Derek Wallace
29 papers receiving 1.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Derek Wallace United States | 16 | 1.2k | 937 | 112 | 81 | 75 | 32 | 1.3k | ||
| Giuliano Silvi Italy | 6 | 1.5k 1.2× | 1.2k 1.3× | 129 1.2× | 73 0.9× | 79 1.1× | 8 | 1.6k | ||
| Wahala M. P. B. Wahala United States | 7 | 1.0k 0.8× | 868 0.9× | 102 0.9× | 108 1.3× | 47 0.6× | 7 | 1.1k | ||
| Alienys Izquierdo Cuba | 14 | 864 0.7× | 659 0.7× | 73 0.7× | 108 1.3× | 48 0.6× | 21 | 973 | ||
| Akhilesh Chandra Mishra India | 14 | 1.0k 0.9× | 1.0k 1.1× | 77 0.7× | 157 1.9× | 47 0.6× | 36 | 1.3k | ||
| Saravudh Suvannadabba Thailand | 10 | 767 0.6× | 647 0.7× | 117 1.0× | 56 0.7× | 49 0.7× | 13 | 911 | ||
| J. Thiria France | 8 | 1.3k 1.1× | 912 1.0× | 213 1.9× | 53 0.7× | 94 1.3× | 9 | 1.4k | ||
| Meng Ling Moi Japan | 23 | 1.3k 1.1× | 1.2k 1.3× | 95 0.8× | 171 2.1× | 171 2.3× | 89 | 1.6k | ||
| Beatríz Sierra Cuba | 18 | 935 0.8× | 835 0.9× | 42 0.4× | 91 1.1× | 38 0.5× | 28 | 1.1k | ||
| Iris Villalobos Venezuela | 7 | 851 0.7× | 641 0.7× | 82 0.7× | 59 0.7× | 75 1.0× | 12 | 905 | ||
| A. B. Sudeep India | 16 | 1.1k 1.0× | 1.0k 1.1× | 118 1.1× | 178 2.2× | 45 0.6× | 45 | 1.4k |
Countries citing papers authored by Derek Wallace
Since
Specialization
Citations
This map shows the geographic impact of Derek Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derek Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derek Wallace more than expected).
Fields of papers citing papers by Derek Wallace
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Derek Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derek Wallace. The network helps show where Derek Wallace may publish in the future.
Co-authorship network of co-authors of Derek Wallace
This figure shows the co-authorship network connecting the top 25 collaborators of Derek Wallace. A scholar is included among the top collaborators of Derek Wallace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Derek Wallace. Derek Wallace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shen, Jing, Samuel Aballéa, Shibadas Biswal, et al.. (2025). Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand. PLoS Medicine. 22(6). e1004631–e1004631.
2.
Fernando, LakKumar, Pujitha Wickramasinghe, Asvini D. Fernando, et al.. (2024). Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience. PLoS neglected tropical diseases. 18(8). e0012376–e0012376.
3.
Tricou, Vianney, Paul Collini, Martina Rauscher, et al.. (2023). A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. Vaccine. 41(7). 1398–1407.
4.
Tricou, Vianney, Brandon Essink, John Ervin, et al.. (2023). Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLoS neglected tropical diseases. 17(3). e0011124–e0011124.
5.
Sáez‐Llorens, Xavier, Shibadas Biswal, Charissa Borja-Tabora, et al.. (2023). Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue. American Journal of Tropical Medicine and Hygiene. 108(4). 722–726.
6.
Pokswinski, Scott, Michael R. Gallagher, Nicholas S. Skowronski, et al.. (2021). A simplified and affordable approach to forest monitoring using single terrestrial laser scans and transect sampling. MethodsX. 8. 101484–101484.
7.
Bugay, Vladislav, Derek Wallace, Bin Wang, et al.. (2020). Bis-Quinolinium Cyclophane Blockers of SK Potassium Channels Are Antagonists of M3 Muscarinic Acetylcholine Receptors. Frontiers in Pharmacology. 11. 552211–552211.
8.
Tricou, Vianney, Xavier Sáez‐Llorens, Delia Yu, et al.. (2020). Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial. The Lancet. 395(10234). 1434–1443.
9.
Jackson, Lisa A., et al.. (2018). A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate. Vaccine. 36(27). 3976–3983.
10.
Jaenisch, Thomas, Liane Agulto, Kay M. Tomashek, et al.. (2018). Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology. BMC Medical Research Methodology. 18(1). 134–134.
11.
Sáez‐Llorens, Xavier, Vianney Tricou, Delia Yu, et al.. (2017). Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. The Lancet Infectious Diseases. 18(2). 162–170.
12.
Sáez‐Llorens, Xavier, Vianney Tricou, Delia Yu, et al.. (2017). Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. The Lancet Infectious Diseases. 17(6). 615–625.
13.
Osorio, Jorge E., Charalambos D. Partidos, Derek Wallace, & Dan T. Stinchcomb. (2015). Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine. 33(50). 7112–7120.
14.
Rupp, Richard, Gary J. Luckasen, Judith L. Kirstein, et al.. (2015). Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. Vaccine. 33(46). 6351–6359.
15.
Sirivichayakul, Chukiat, Helen Oh, Marsha G. Raanan, et al.. (2015). Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. The Journal of Infectious Diseases. 213(10). 1562–1572.
16.
Torresi, Joseph, Leon Heron, Ming Qiao, et al.. (2015). Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study. Vaccine. 33(39). 5127–5134.
17.
Osorio, Jorge E., Derek Wallace, & Dan T. Stinchcomb. (2015). A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Review of Vaccines. 15(4). 497–508.
18.
Wallace, Derek, et al.. (2013). Challenges in the clinical development of a dengue vaccine. Current Opinion in Virology. 3(3). 352–356.
19.
Sabchareon, Arunee, Derek Wallace, Chukiat Sirivichayakul, et al.. (2012). Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet. 380(9853). 1559–1567.
20.
Wallace, Derek. (2011). Governing the Future.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Giuliano Silvi Breakdown of academic impact, for papers by Wahala M. P. B. Wahala Breakdown of academic impact, for papers by Alienys Izquierdo Breakdown of academic impact, for papers by Akhilesh Chandra Mishra Breakdown of academic impact, for papers by Saravudh Suvannadabba Breakdown of academic impact, for papers by J. Thiria Breakdown of academic impact, for papers by Meng Ling Moi Breakdown of academic impact, for papers by Beatríz Sierra Breakdown of academic impact, for papers by Iris Villalobos Breakdown of academic impact, for papers by A. B. Sudeep